Slow-, tight-binding HIV-1 reverse transcriptase non-nucleoside inhibitors highly active against drug-resistant mutants

被引：21
作者：
Cancio, Reynel
Mai, Antonello
Rotili, Dante
Artico, Marino
Sbardella, Gianluca
Clotet-Codina, Imma
Este, Jose A.
Crespan, Emmanuele
Zanoli, Samantha
Hubscher, Ulrich
Spadari, Silvio
Maga, Giovanni
机构：
[1] Istituto di Genetica Molecolare, Consiglio Nazionale Delle Ricerche, 27100 Pavia
[2] Istituto Pasteur-Fondazione Cenci Bolognetti, Dipartimento di Studi Farmaceutici, Università degli Studi di Roma La Sapienza, 00185 Roma
[3] Dipartimento di Scienze Farmaceutiche, Università degli Studi di Salerno, 84084 Fisciano (SA), via Ponte Don Melillo
[4] Retrovirology Laboratory IrsiCaixa, Hospital Universitari Germans Trias I Pujol, Universitat AutAnoma de Barcelona
[5] Institute of Veterinary Biochemistry and Molecular Biology, University of Zürich-Irchel, 8057 Zürich
来源：
CHEMMEDCHEM | 2007年 / 2卷 / 04期
关键词：
D O I：
10.1002/cmdc.200600310
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
(Chemical Equation Presented) A new series of dihydro-alkylaminobenzyl- oxopyrimidines (N,N-DABOs) showing a broad activity spectrum against NNRTI-resistant mutants have been reported. Such compounds display a slow, tight binding to HIV-1 RT. © 2007 Wiley-VCH Verlag GmbH & Co. KGaA.
引用
收藏
页码：445 / 448
页数：4
相关论文
共 21 条
[1]   The anti-HIV activity of ADS-J1 targets the HIV-1 gp120 [J].
Armand-Ugón, M ;
Clotet-Codina, I ;
Tintori, C ;
Manetti, F ;
Clotet, B ;
Botta, M ;
Esté, JA .
VIROLOGY, 2005, 343 (01) :141-149
[2]   3,4-DIHYDRO-2-ALKOXY-6-BENZYL-4-OXOPYRIMIDINES (DABOS) - A NEW CLASS OF SPECIFIC INHIBITORS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
ARTICO, M ;
MASSA, S ;
MAI, A ;
MARONGIU, ME ;
PIRAS, G ;
TRAMONTANO, E ;
LACOLLA, P .
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1993, 4 (06) :361-368
[3]   Selected non-nucleoside reverse transcriptase inhibitors (NNRTIs): the DABOs family [J].
Artico, M .
DRUGS OF THE FUTURE, 2002, 27 (02) :159-175
[4]   Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: Past, present, and future perspectives [J].
Campiani, G ;
Ramunno, A ;
Maga, G ;
Nacci, V ;
Fattorusso, C ;
Catalanotti, B ;
Morelli, E ;
Novellino, E .
CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (08) :615-657
[5]  
DANEL K, 1998, BIOORG MED CHEM LETT, V8, P1461
[6]   Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Past, present, and future [J].
De Clercq, E .
CHEMISTRY & BIODIVERSITY, 2004, 1 (01) :44-64
[7]   The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection [J].
De Clercq, E .
ANTIVIRAL RESEARCH, 1998, 38 (03) :153-179
[8]  
De Clercq Erik, 2005, Expert Opin Emerg Drugs, V10, P241, DOI 10.1517/14728214.10.2.241
[9]   5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thiol-6(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series [J].
He, YP ;
Chen, FN ;
Sun, GF ;
Wang, YP ;
De Clercq, E ;
Balzarini, J ;
Pannecouque, C .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (12) :3173-3176
[10]   Antiretroviral therapy of HIV-1 infection: established treatment strategies and new therapeutic options [J].
Kaufmann, GR ;
Cooper, DA .
CURRENT OPINION IN MICROBIOLOGY, 2000, 3 (05) :508-514
123